157 related articles for article (PubMed ID: 11372590)
1. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
[TBL] [Abstract][Full Text] [Related]
2. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
[TBL] [Abstract][Full Text] [Related]
4. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
7. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
8. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
9. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.
Gaedigk A; Casley WL; Tyndale RF; Sellers EM; Jurima-Romet M; Leeder JS
Can J Physiol Pharmacol; 2001 Oct; 79(10):841-7. PubMed ID: 11697742
[TBL] [Abstract][Full Text] [Related]
11. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
[TBL] [Abstract][Full Text] [Related]
12. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines.
Yilmaz N; Erbağci AB; Aynacioğlu AS
Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786
[TBL] [Abstract][Full Text] [Related]
14. Genetic analysis of the human cytochrome P450 CYP2C9 locus.
Stubbins MJ; Harries LW; Smith G; Tarbit MH; Wolf CR
Pharmacogenetics; 1996 Oct; 6(5):429-39. PubMed ID: 8946475
[TBL] [Abstract][Full Text] [Related]
15. Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?
Martin JH; Begg EJ; Kennedy MA; Roberts R; Barclay ML
Br J Clin Pharmacol; 2001 Jun; 51(6):627-30. PubMed ID: 11422024
[TBL] [Abstract][Full Text] [Related]
16. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
17. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
18. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
19. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
